Triglyceride-focused highlights from the 92nd Annual Congress of the European Atherosclerosis Society (26-29 May 2024, Lyon, France, and online) included recently published human genetic studies supporting the potential of ANGPTL3/4 inhibition in the prevention of atherosclerotic cardiovascular disease (ASCVD), final results from the ARCHES-2 and MUIR trials of the effects of ANGPTL3 and ApoC3 targeting therapies on elevated TG levels in patients with mixed hyperlipidaemia, and latest preclinical data on ANGPTL3 gene editing.
Read the reports:
- ANGPTL3/4 inhibition: Genetic studies support potential for heart disease
- ARCHES-2 trial shows durable TG reductions with zodasiran
- MUIR data reported for plozasiran at 48 weeks
- VERVE-201: ANGPTL3 and lipid reductions maintained up to 22 months
Reportage by Jenny Bryan
